Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Albert Einstein College of Medicine
Hoosier Cancer Research Network
University Hospital Heidelberg
University Health Network, Toronto
University of Chicago
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Rutgers, The State University of New Jersey
Sumitomo Pharma America, Inc.
AstraZeneca
Cedars-Sinai Medical Center
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Fudan University
Ohio State University Comprehensive Cancer Center
MacroGenics
Columbia University
Emory University
Medical College of Wisconsin
University of Nebraska
University of Nebraska
National Cancer Institute (NCI)
University of Washington
Medical College of Wisconsin
Novartis
Brigham and Women's Hospital
National Institutes of Health Clinical Center (CC)
Aarhus University Hospital
University of Cincinnati
University of Pittsburgh
AIDS Malignancy Consortium
Massachusetts Eye and Ear Infirmary
Massachusetts General Hospital
Assistance Publique Hopitaux De Marseille
Universitair Ziekenhuis Brussel
Incyte Corporation
Weill Medical College of Cornell University
LigaChem Biosciences, Inc.
Merck Sharp & Dohme LLC
Washington University School of Medicine
UNICANCER
Institut Claudius Regaud
Travera Inc
Sahlgrenska University Hospital
Federation Francophone de Cancerologie Digestive
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Washington University School of Medicine
Icahn School of Medicine at Mount Sinai